Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.59 |
| ▸ | PGGT1B | P53609 | 13/20 | 0.59 |
| ▸ | FNTB | P49356 | 12/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775315 | 1.00 | FNTA (0.59) | FNTAPGGT1BFNTBTDP1TAS1R3 | |
| SCHEMBL16136628 | 0.92 | FNTA (0.71) | FNTAPGGT1BFNTB | |
| SCHEMBL7608404 | 0.92 | FNTA (0.71) | FNTAPGGT1BFNTB | |
| Hydrochloric Acid SCHEMBL6776199 | 0.91 | FNTA (0.70) | FNTAPGGT1BFNTB | |
| SCHEMBL17548781 | 0.91 | FNTA (0.55) | FNTAPGGT1BFNTBTDP1MEN1 | |
| SCHEMBL10018886 | 0.90 | FNTA (0.66) | FNTAPGGT1BFNTBTDP1TAS1R3 | |
| SCHEMBL6775184 | 0.83 | FNTA (0.69) | FNTAPGGT1BFNTB | |
| SCHEMBL4280385 | 0.81 | FNTA (0.78) | FNTAPGGT1BFNTBTDP1BCL2L1 | |
| SCHEMBL20564402 | 0.81 | FNTA (0.61) | FNTAPGGT1BFNTBTDP1MEN1 | |
| SCHEMBL6782079 | 0.78 | FNTA (0.63) | FNTAPGGT1BFNTBTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014160729-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS RESEARCH INDIA PVT. LTD (IN) | 2014-10-02 | — | — | WO | disclosed |
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | FNTA 20/4885PGGT1B 1021/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.